Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases

Erwin Dreesen,1 Peter Bossuyt,2,3 Denis Mulleman,4 Ann Gils,1 Dora Pascual-Salcedo5 1Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, 2Imelda GI Clinical Research Centre, Imelda Ziekenhuis, Bonheiden, 3Translational R...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	therapeutic drug monitoring biopharmaceuticals trough concentration immunogenicity antidrug antibodies inflammatory diseases Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/61d373e54a0b44709abc4a0fe9b8bfe9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61d373e54a0b44709abc4a0fe9b8bfe9
record_format	dspace
spelling	oai:doaj.org-article:61d373e54a0b44709abc4a0fe9b8bfe92021-12-02T01:54:29ZPractical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases1179-1438https://doaj.org/article/61d373e54a0b44709abc4a0fe9b8bfe92017-10-01T00:00:00Zhttps://www.dovepress.com/practical-recommendations-for-the-use-of-therapeutic-drug-monitoring-o-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Erwin Dreesen,1 Peter Bossuyt,2,3 Denis Mulleman,4 Ann Gils,1 Dora Pascual-Salcedo5 1Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, 2Imelda GI Clinical Research Centre, Imelda Ziekenhuis, Bonheiden, 3Translational Research in GastroIntestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium; 4Department of Rheumatology, Université François-Rabelais de Tours, CNRS, UMR 7292, Tours, France; 5Institute for Research IdiPAZ, University Hospital La Paz, Madrid, Spain Abstract: Biopharmaceuticals directed against tumor necrosis factor-alpha, integrins, interleukins, interferons and their receptors have become key agents for the management of inflammatory diseases in the fields of gastroenterology, rheumatology, dermatology and neurology. However, response to these treatments is far from optimal. Therapeutic failure has been attributed in part to inadequate serum concentrations of the drug and the formation of antidrug antibodies (ADA). Therapeutic drug monitoring (TDM) based on drug concentrations and ADA represents a pharmacologically sound tool for guiding dosage adjustments to optimize exposure. Although becoming standard practice in tertiary care centers, the widespread accessibility and recognition of TDM is hindered by several hurdles, including a lack of education of health care providers on TDM. In this paper, the Monitoring of monoclonal Antibodies Group in Europe (MAGE) provides an introduction on the fundamental principles of the concept of TDM, aiming to educate clinicians and assist them in the process of implementing TDM of anti-inflammatory biopharmaceuticals. Keywords: therapeutic drug monitoring, biopharmaceuticals, trough concentration, immunogenicity, antidrug antibodies, inflammatory diseases Dreesen EBossuyt PMulleman DGils APascual-Salcedo DDove Medical Pressarticletherapeutic drug monitoringbiopharmaceuticalstrough concentrationimmunogenicityantidrug antibodiesinflammatory diseasesTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 9, Pp 101-111 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	therapeutic drug monitoring biopharmaceuticals trough concentration immunogenicity antidrug antibodies inflammatory diseases Therapeutics. Pharmacology RM1-950
spellingShingle	therapeutic drug monitoring biopharmaceuticals trough concentration immunogenicity antidrug antibodies inflammatory diseases Therapeutics. Pharmacology RM1-950 Dreesen E Bossuyt P Mulleman D Gils A Pascual-Salcedo D Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
description	Erwin Dreesen,1 Peter Bossuyt,2,3 Denis Mulleman,4 Ann Gils,1 Dora Pascual-Salcedo5 1Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, 2Imelda GI Clinical Research Centre, Imelda Ziekenhuis, Bonheiden, 3Translational Research in GastroIntestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium; 4Department of Rheumatology, Université François-Rabelais de Tours, CNRS, UMR 7292, Tours, France; 5Institute for Research IdiPAZ, University Hospital La Paz, Madrid, Spain Abstract: Biopharmaceuticals directed against tumor necrosis factor-alpha, integrins, interleukins, interferons and their receptors have become key agents for the management of inflammatory diseases in the fields of gastroenterology, rheumatology, dermatology and neurology. However, response to these treatments is far from optimal. Therapeutic failure has been attributed in part to inadequate serum concentrations of the drug and the formation of antidrug antibodies (ADA). Therapeutic drug monitoring (TDM) based on drug concentrations and ADA represents a pharmacologically sound tool for guiding dosage adjustments to optimize exposure. Although becoming standard practice in tertiary care centers, the widespread accessibility and recognition of TDM is hindered by several hurdles, including a lack of education of health care providers on TDM. In this paper, the Monitoring of monoclonal Antibodies Group in Europe (MAGE) provides an introduction on the fundamental principles of the concept of TDM, aiming to educate clinicians and assist them in the process of implementing TDM of anti-inflammatory biopharmaceuticals. Keywords: therapeutic drug monitoring, biopharmaceuticals, trough concentration, immunogenicity, antidrug antibodies, inflammatory diseases
format	article
author	Dreesen E Bossuyt P Mulleman D Gils A Pascual-Salcedo D
author_facet	Dreesen E Bossuyt P Mulleman D Gils A Pascual-Salcedo D
author_sort	Dreesen E
title	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
title_short	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
title_full	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
title_fullStr	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
title_full_unstemmed	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
title_sort	practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/61d373e54a0b44709abc4a0fe9b8bfe9
work_keys_str_mv	AT dreesene practicalrecommendationsfortheuseoftherapeuticdrugmonitoringofbiopharmaceuticalsininflammatorydiseases AT bossuytp practicalrecommendationsfortheuseoftherapeuticdrugmonitoringofbiopharmaceuticalsininflammatorydiseases AT mullemand practicalrecommendationsfortheuseoftherapeuticdrugmonitoringofbiopharmaceuticalsininflammatorydiseases AT gilsa practicalrecommendationsfortheuseoftherapeuticdrugmonitoringofbiopharmaceuticalsininflammatorydiseases AT pascualsalcedod practicalrecommendationsfortheuseoftherapeuticdrugmonitoringofbiopharmaceuticalsininflammatorydiseases
_version_	1718402841937182720

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases

Ejemplares similares